中国医药
中國醫藥
중국의약
CHINA MEDICINE
2009年
2期
103-104
,共2页
刘姝梅%杨海涛%季淑玉%郭式敦
劉姝梅%楊海濤%季淑玉%郭式敦
류주매%양해도%계숙옥%곽식돈
非小细胞肺癌%吉西他滨%长春瑞滨%顺铂
非小細胞肺癌%吉西他濱%長春瑞濱%順鉑
비소세포폐암%길서타빈%장춘서빈%순박
Non-small cell lung cancer%Gemcitabine%Navelbine%Cisplation
目的 评价吉西他滨联合顺铂(GP方案)与长春瑞滨联合顺铂(NP方案)治疗晚期非小细胞肺癌(NSCLC)的疗效和不良反应.方法 85例晚期NSCLC患者采用完全随机法分为GP组42例和NP组43例.分别用GP方案和NP方案化疗2个周期后对2组的临床疗效和不良反应进行评价.结果 GP组有效率为40.5%,NP组为39.5%,2组间比较差异无统计学意义(P>0.05).2组不良反应主要为骨髓抑制,GP组血小板减少高于NP组(P<0.05),NP组白细胞下降高于GP组(P<0.05),均可耐受.结论 吉西他滨或长春瑞滨联合顺铂治疗晚期NSCLC具有较好的耐受性和临床疗效,不良反应有所不同,但都可以耐受.
目的 評價吉西他濱聯閤順鉑(GP方案)與長春瑞濱聯閤順鉑(NP方案)治療晚期非小細胞肺癌(NSCLC)的療效和不良反應.方法 85例晚期NSCLC患者採用完全隨機法分為GP組42例和NP組43例.分彆用GP方案和NP方案化療2箇週期後對2組的臨床療效和不良反應進行評價.結果 GP組有效率為40.5%,NP組為39.5%,2組間比較差異無統計學意義(P>0.05).2組不良反應主要為骨髓抑製,GP組血小闆減少高于NP組(P<0.05),NP組白細胞下降高于GP組(P<0.05),均可耐受.結論 吉西他濱或長春瑞濱聯閤順鉑治療晚期NSCLC具有較好的耐受性和臨床療效,不良反應有所不同,但都可以耐受.
목적 평개길서타빈연합순박(GP방안)여장춘서빈연합순박(NP방안)치료만기비소세포폐암(NSCLC)적료효화불량반응.방법 85례만기NSCLC환자채용완전수궤법분위GP조42례화NP조43례.분별용GP방안화NP방안화료2개주기후대2조적림상료효화불량반응진행평개.결과 GP조유효솔위40.5%,NP조위39.5%,2조간비교차이무통계학의의(P>0.05).2조불량반응주요위골수억제,GP조혈소판감소고우NP조(P<0.05),NP조백세포하강고우GP조(P<0.05),균가내수.결론 길서타빈혹장춘서빈연합순박치료만기NSCLC구유교호적내수성화림상료효,불량반응유소불동,단도가이내수.
Objective To evaluate side effects of gemcitabine plus cisplation (GP Programme) therapy and navelbine plus cisplation (NP programme) therapy for non-small cell lung cancer (NSCLC). Methods Eight-five advanced non-small cell lung cancer patients were divided into 2 groups: 42 with GP and 43 with NP. Results The response rates of GP and NP group were 40.5% and 39.5% respectively. There was no significant difference in response rate between the two groups (P>0.05). The major adverse reactions were myelosuppression. Thrombocytopenia in GP Group was higher than NP group, leukopenia in NP Group was higher than GP group. Conclusion Both GP and NP regimens are effective for advanced NSCLC. The side effects of the two regimens are different but all adverse reactions are tolerable.